Practising computer-aided objectified outcome-driven targeted treatment of rheumatoid arthritis in a resource constrained country: results from a single rheumatology clinic

Indian Journal of Rheumatology

Volumn 5, Issue 1, 2010, Pages 3-10

  Malaviya, AN ^a   Agarwal, D ^a   Sharma, A ^a   Gogia, SB ^b   Zaheer, Q ^a  

^a ISIC Superspeciality Hospital   (India)

^b Indian Association for Medical Informatics   (India)

Author keywords

CDAI; DAS28; outcome measures; outcome driven; Rheumatoid arthritis; rheumatology software; targeted treatment

Indexed keywords

DEOXYCHOLIC ACID; HYDROXYCHLOROQUINE; LEFLUNOMIDE; LIVER ENZYME; METHOTREXATE; METHYLPREDNISOLONE; SALAZOSULFAPYRIDINE;

ARTICLE; COMPUTER AIDED DESIGN; DISEASE ACTIVITY; FOLLOW UP; FUNCTIONAL STATUS; GASTROINTESTINAL SYMPTOM; HEALTH CARE PERSONNEL; HUMAN; INFORMATION PROCESSING; LEUKOPENIA; MAJOR CLINICAL STUDY; MEDICAL INFORMATION; NAUSEA; OUTPATIENT DEPARTMENT; PATIENT ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE;

EID: 84992255303     PISSN: 09733698     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0973-3698(10)60529-8     Document Type: Article

References (24)

1. Saag K.G., Teng G.G., Patkar N.M., Anuntiyo J., Finney C., Curtis J.R., et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 59 (2008) 762-784
2. Visser K., Katchamart W., Loza E., Martinez-Lopez J.A., Salliot C., Trudeau J., et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 68 (2008) 1086-1093
3. Visser K., and van der Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis 68 (2008) 1094-1099
4. Bijlsma J.W., and Weinblatt M.E. Optimal use of methotrexate: the advantages of tight control. Ann Rheum Dis 66 (2007) 1409-1410
5. Verstappen S.M., Jacobs J.W., van der Veen M.J., Heurkens A.H., Schenk Y., ter Borg E.J., et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 66 (2007) 1443-1449
6. Pincus T., Yazici Y., Sokka T., Aletaha D., and Smolen J.S. Methotrexate as the 'anchor drug' for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol 21 (2003) S179-S185
7. Combe B., Landewe R., Lukas C., Bolosiu H.D., Breedveld F., Dougados M., et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 66 1 (2007) 34-45
8. Choy E., Smith C.M., Farewell V., Walker D., Hassell A., Chau L., et al. Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis. Ann Rheum Dis 67 (2008) 656-663
9. van Tuyl L.H.D., Lems W.F., Voskuyl A.E., Kerstens P.J.S.M., Garnero P., Dijkmans B., et al. Tight control and intensified COBRA combination treatment in early rheumatoid arthritis: 90% remission in a pilot trial. Ann Rheum Dis 67 (2008) 1574-1577
10. Korpela M., Laasonen L., for the FIN-RACo Trial Group, Hannonen P., Kautiainen H., Leirisalo-Repo M., et al. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: Five-year experience from the FIN-RACo study. Arthritis Rheum 50 (2004) 2072-2081
11. Goekoop-Ruiterman Y.P., de Vries-Bouwstra J.K., Allaart C.F., et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 52 (2005) 3381-3390
12. van der Kooij S.M., Goekoop-Ruiterman Y., Vries-Bouwstra J.K., Peeters A.J., van Krugten M.V., Breedveld F.C., et al. Probability of continued low disease activity in patients with recent onset rheumatoid arthritis treated according to the disease activity score. Ann Rheum Dis 67 (2008) 266-269
13. Hetland M.L., Stengaard-Pedersen K., Junker P., Lottenburger T., Hansen I., Andersen L.S., et al. Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second-year clinical and radiographic results from the CIMESTRA study. Ann Rheum Dis 67 (2008) 815-822
14. Scott D.L., Antoni C., Choy E.H., and van Riel P.C.L.M. Joint counts in routine practice. Rheumatology 42 8 (2003) 919-923
15. Grigor C., Capell H., Stirling A., McMahon A.D., Lock P., Vallance R., et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364 (2004) 263-269
16. Fransen J., Moens H.B., Speyer I., and van Riel P.L. Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial. Ann Rheum Dis 64 (2005) 1294-1298
17. Bakker M.F., Jacobs J.W.G., Verstappen S.M.M., and Bijlsma J.W.J. Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. Ann Rheum Dis 66 Suppl 3 (2007) iii56-iii60
18. Prevoo M.L., 't Hof M.A., Kuper H.H., van Leeuwen M.A., van de Putte L.B., and van Riel P.L. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38 (1995) 44-48
19. Aletaha D., Ward M.M., Machold K.P., Nell V.P., Stamm T., and Smolen J.S. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum 52 (2005) 2625-2636
20. Aletaha D., and Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 23 (2005) S100-S108
21. Kumar A., Malaviya A.N., Pandhi A., and Singh R. Validation of an Indian version of the Health Assessment Questionnaire in patients with rheumatoid arthritis. Rheumatology (Oxford) 41 (2002) 1457-1459
22. Arya V., Malaviya A.N., and Raja R.R. CDAI (clinical disease activity index) in rheumatoid arthritis: cut-off values for classification into different grades of disease activity. Ind J Rheumatol 2 (2007) 91-94
23. Anderson J.J., Wells G., Verhoeven A.C., and Felson D.T. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 43 (2000) 22-29
24. Malaviya A.N., Mehra N.K., Dasgupta B., Khan K.M., Rao U., Aggarwal A., et al. Clinical and immunogenetic studies in rheumatoid arthritis in India. Rheumatol Int 3 (1983) 105-108